Oncology
Myelofibrosis
Conference Reporter® Podcast: Progressive Disease in Myelofibrosis
Despite meaningful advances with JAK inhibitors and other medical therapies, progressive disease remains a defining challenge in myelofibrosis, and allogeneic transplantation continues to hold a unique role as the only potentially curative option. In today’s podcast, Aaron T. Gerds, MD, MS, discusses evolving approaches to transplantation, JAK inhibitor failure, imetelstat-based strategies, and anemia-directed therapy, drawing on presentations from the 2026 ASCO Annual Meeting.
Following these presentations, featured expert Aaron T. Gerds, MD, MS, was interviewed by Conference Reporter Associate Editor-in-Chief Rick Davis, MS, RPh. Clinical perspectives from Dr Gerds on these findings are presented here.
Gangat N, Tefferi A, Bose P, et al. RALLY-MF: initial efficacy of a phase 2 study of DISC-0974, an anti-hemojuvelin antibody, to treat anemia in myelofibrosis [abstract 6501] [session: Hematologic malignancies—leukemia, myelodysplastic syndromes, and allotransplant]. Abstract presented at: 2026 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2026; Chicago, IL.
Gerds AT, Fleischman AG, Mascarenhas J, et al. Expert perspectives in the management of myelofibrosis (MF): a survey of 20 US-based specialists [abstract e18590] [session: Publication only: hematologic malignancies—leukemia, myelodysplastic syndromes, and allotransplant]. Abstract presented at: 2026 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2026; Chicago, IL. Accessed July 22, 2026. https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.e18590
Kuykendall AT, Qasim H, Araji G, et al. Updated analysis of overall survival (OS) with imetelstat (IME) in relapsed/refractory (R/R) myelofibrosis (MF) versus real-world (RW) data, and assessment of RW treatment (tx) patterns [abstract 6573] [session: Hematologic malignancies—leukemia, myelodysplastic syndromes, and allotransplant]. Poster presented at: 2026 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2026; Chicago, IL.
Mascarenhas J, Kuykendall AT, Bradley TJ, et al. Updated protocol: IMproveMF, a phase 1b trial of imetelstat (IME) + ruxolitinib (RUX) in patients (pts) with intermediate (INT)-1/2 or high-risk (HR) myelofibrosis (MF) [abstract TPS6604] [session: Hematologic malignancies—leukemia, myelodysplastic syndromes, and allotransplant]. Poster presented at: 2026 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2026; Chicago, IL.
This information is brought to you by Engage Health Media and is not sponsored, endorsed, or accredited by the American Society of Clinical Oncology.
